Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 570-574

  Klimek, Virginia M ^a   Dolezal, Emily K ^a   Smith, Larry ^a   Soff, Gerald ^a   Nimer, Stephen D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Myelodysplastic syndromes; NF B; Sodium salicylate

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SALICYLATE SODIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BALANCE IMPAIRMENT; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEARING LOSS; HUMAN; IN VITRO STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TINNITUS;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVER; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NF-KAPPA B; PLATELET AGGREGATION; SODIUM SALICYLATE;

EID: 84858751230     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.10.023     Document Type: Article

References (29)

1. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
2. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5:412-417.
3. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
4. Fabre C., Carvalho G., Tasdemir E., Braun T., Ades L., Grosjean J., et al. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007, 26:4071-4083.
5. Carvalho G., Fabre C., Braun T., Grosjean J., Ades L., Agou F., et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007, 26:2299-2307.
6. Bueso-Ramos C.E., Rocha F.C., Shishodia S., Medeiros L.J., Kantarjian H.M., Vadhan-Raj S., et al. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol 2004, 35:246-253.
7. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
8. Frelin C., Imbert V., Griessinger E., Peyron A.C., Rochet N., Philip P., et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005, 105:804-811.
9. Birkenkamp K.U., Geugien M., Schepers H., Westra J., Lemmink H.H., Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-112.
10. Majeti R., Becker M.W., Tian Q., Lee T-LM, Yan X., Liu R., et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A 2009, 106:3396-3401.
11. Reya T., Duncan A.W., Ailles L., Domen J., Scherer D.C., Willert K., et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003, 423:409-414.
12. Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
13. Goessling W., North T.E., Loewer S., Lord A.M., Lee S., Stoick-Cooper C.L., et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009, 136:1136-1147.
14. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
15. Klampfer L., Cammenga J., Wisniewski H.G., Nimer S.D. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 1999, 93:2386-2394.
16. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
17. Cheson B., Cassileth P., Head D., Schiffer C., Bennett J., Bloomfield C., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990, 8:813-819.
18. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
19. Derouet M., Thomas L., Moulding D.A., Akgul C., Cross A., Moots R.J., et al. Sodium salicylate promotes neutrophil apoptosis by stimulating caspase-dependent turnover of Mcl-1. J Immunol 2006, 176:957-965.
20. Romano M.F., Lamberti A., Bisogni R., Tassone P., Pagnini D., Storti G., et al. Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel-specific decoy oligodeoxynucleotides. Gene Ther 2000, 7:1234-1237.
21. Wang C.Y., Mayo M.W., Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 274:784-787.
22. Romano M.F., Petrella A., Bisogni R., Turco M.C., Venuta S. Effect of NF-kappaB/Rel inhibition on spontaneous vs chemotherapy-induced apoptosis in AML and normal cord blood CD34+ cells. Leukemia 2003, 17:1190-1192.
23. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002, 99:16220-16225.
24. Guzman M.L., Rossi R.M., Karnischky L., Li X., Peterson D.R., Howard D.S., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163-4169.
25. Shetty V., Verspoor F., Nguyen H., Gallegos A., Mundle S.D., Chaudhry N. Effect of proteosome inhibition by bortezomib on tumor necrosis factor-alpha (TNF-alpha) and apoptosis in patients with myelodysplastic syndromes (MDS). Blood 2003, 102. [Abstract 1534].
26. Dai Y., Guzman M.L., Chen S., Wang L., Yeung S.K., Pei X.Y., et al. The NF (nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 2010, 151:70-83.
27. Attar E.C., De Angelo D.J., Supko J.G., D'Amato F., Zahrieh D., Sirulnik A., et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008, 14:1446-1454.
28. Strair R.K., Gharibo M., Schaar D., Rubin A., Harrison J., Aisner J., et al. Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia. Clin Cancer Res 2008, 14:7564-7568.
29. Hall J.G., Cory A.H., Hickerson D.H., Cory J.G. Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells. Anticancer Res 2001, 21:173-180.